Motexafin lutetium hydrate

This product is for research use only, not for human use. We do not sell to patients.

For small sizes, please check our retail website as below: www.invivochem.com

Size	Price	Stock
2mg	$450	3-6 Days
5mg	$650	3-6 Days
10mg	$1050	3-6 Days
25mg	$1950	3-6 Days
50mg	$3250	3-6 Days

: [email protected] [email protected]

Cat #: V3903 CAS #: 156436-90-7 Purity ≥ 98%

Description: Motexafin lutetium hydrate (PCI-0123; Antrin; PCI0123; Lu texaphyrin; PCI 0123; LuTex; Lutetium texaphyrin; Lutrin; Optrin), the hydrated form of Motexafin lutetium, is a pentadentate aromatic metallotexaphyrin with photosensitizing properties. It is a photosensitiser used in photodynamic therapy to treat skin conditions and superficial cancers. It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries). It is photoactivated by 732 nm light which allows greater depth of penetration.

Top Publications Citing Invivochem Products

Product Catalog 2022

Guide to Product Handling

Publications Citing InvivoChem Products

Product Promise

Physicochemical and Storage Information
Protocol
Related Biological Data
Stock Solution Preparation
Quality Control Documentation

Molecular Weight (MW)	1166.12
Molecular Formula	C52H74LuN5O15
CAS No.	156436-90-7
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility In Vitro	DMSO: N/A
	Water: N/A
	Ethanol: N/A
SMILES Code	CCC1=C2N3C(C=C4C(CCCO)=C(C)C(C=[N]5C6=C7C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=C6)=[N]4[Lu+3]358([O-]C(C)=O)([O-]C(C)=O)[N]9=C(C=[N]78)C(C)=C(CCCO)C9=C2)=C1CC
Synonyms	PCI-0123; Lutetium texaphyrin; Lu texaphyrin; PCI 0123; Lutrin; Optrin; PCI0123; LuTex; trade name: Antrin.

Related Biological Data

Time course of PSA response to PDT in patient 17 (A) and of the patient-averaged (mean ± SE) percent change in PSA after PDT (B). Clinical Cancer Research. 2008, 14 (15): 4869–76.

The average (mean ± SE) percent change in PSA, a function of time after PDT in patients who experienced a PDT dose less than (open bars) or greater than or equal to (closed bars), the median dose of 116 PDT dose was calculated as the product of tissue photosensitizer concentration and light dose, n = 4 to 6 (open bars) or 7 to 8 (closed bars). +, = P < 0.06 for Wilcoxon signed-rank test comparing post-PDT PSA values to baseline measurement in the same patient. Clinical Cancer Research. 2008, 14 (15): 4869–76.

Kaplan-Meier estimation of biochemical delay in the PSA response in patients treated with a PDT dose less than or greater than or equal to the median dose of 116 Duration of biochemical delay was defined as the length of time between PDT and a nonreversible (i.e., not PDT induced) increase in PSA to a value greater than or equal to baseline. n = 6 and 8 for low- and high-dose PDT, respectively. Clinical Cancer Research. 2008, 14 (15): 4869–76.

Preparing Stock Solutions

Solvent volume to be added	Mass (the weight of a compound)
Mother liquor concentration	1mg	5mg	10mg	20mg
1mM	0.8575 mL	4.2877 mL	8.5754 mL	17.1509 mL
5mM	0.1715 mL	0.8575 mL	1.7151 mL	3.4302 mL
10mM	0.0858 mL	0.4288 mL	0.8575 mL	1.7151 mL
20mM	0.0429 mL	0.2144 mL	0.4288 mL	0.8575 mL

Quality Control Documentation	Select Batch Purity ≥ 98% COA MSDS NMR HPLC

The molarity calculator equation

Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)

Mass

Concentration

Volume

Molecular Weight*

The dilution calculator equation

Concentration_(start) × Volume_(start) = Concentration_(final) × Volume_(final)

This equation is commonly abbreviated as: C₁ V₁ = C₂ V₂

Concentration_(start)

Volume_(start)

Concentration_(final)

Volume_(final)

Step One: Enter information below

Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals

Step Two: Enter the in vivo formulation

%DMSO + % + %Tween 80 + %ddH₂O

Calculation Results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH₂O,mix and clarify.

Note:

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.